ArticleJournal of Crohn's & colitis2021
Vitamin D Levels May Predict Response to Vedolizumab.
Giorgos Bamias, Jesús Rivera-Nieves
Abstract readEditorialComment
In one paragraphArticle in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
2 authors.
Giorgos BamiasGI Unit, 3rd Academic Dept. of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.ORCID 0000-0002-5492-5717 Jesús Rivera-NievesInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego [UCSD], La Jolla, CA, USA.
Funding
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8MNovel Traffic-targeted Therapies for IBDR01DK108670 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2016 to 2020
$3.3MImmunoprofiling for identifying biomarkers in celiac diseaseR21AI149636 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ERNST, PETER B., RIVERA-NIEVES, JESUS · 2020 to 2021
$433kHigh Dimensional Mass Cytometry Analysis of the Effects of Vedolizumab in Intestinal Cellular Subsets and its Correlation with Clinical ParametersR21DK118927 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2019 to 2020
$392kDendritic Cell Regulation by Sphingosine-1-phosphate in Inflammatory Bowel DiseaseI01BX003436 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI RIVERA-NIEVES, JESUS · 2019 to 2022
–BLRD VA I01 BX003436Mucosal Immunology, Allergy and VaccinesNIAID NIH HHS R21 AI149636NIDDK NIH HHS P30 DK120515NIDDK NIH HHS R01 DK108670NIDDK NIH HHS R21 DK118927NIH HHS DK108670Takeda Pharmaceuticals IISR-2017-102050Takeda Pharmaceuticals U.S.A. IISR-2017-102050
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedVitamin DGastrointestinal AgentsHumansAntibodies, Monoclonal, HumanizedGastrointestinal AgentsvedolizumabVitamin D
Identifiers
PMID34185075
PMCPMC8684447
What OpenQuestion holds
Textmetadata
Read underepoch 390